{"transactions":[{"id":961077,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70978,"kind":"person","name":"Bhatia Kishor G.","position":1,"cik":"0001812638","reported_name":"Bhatia Kishor G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-22T16:05:24.000Z","date":"2025-12-18","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing January 18, 2026."}],"balance_after":10000,"derivative":{"exercise_price":3.24,"expiration_date":"2035-12-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001493152-25-028758","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812638/000149315225028758/ownership.xml","form_type":"4"}},{"id":1033809,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70978,"kind":"person","name":"Bhatia Kishor G.","position":1,"cik":"0001812638","reported_name":"Bhatia Kishor G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:14.000Z","date":"2021-10-29","kind":"grant","planned":false,"acquired":true,"shares":17400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021."}],"balance_after":17400,"derivative":{"exercise_price":5.04,"expiration_date":"2031-10-28","underlying":"Common Stock","underlying_shares":17400},"source":{"system":"sec-edgar","filing":"0001493152-25-014615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1812638/000149315225014615/ownership.xml","form_type":"4"}},{"id":1033808,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70978,"kind":"person","name":"Bhatia Kishor G.","position":1,"cik":"0001812638","reported_name":"Bhatia Kishor G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:14.000Z","date":"2021-10-29","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021."}],"balance_after":0,"derivative":{"exercise_price":10.21,"expiration_date":"2031-10-28","underlying":"Common Stock","underlying_shares":17400},"source":{"system":"sec-edgar","filing":"0001493152-25-014615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1812638/000149315225014615/ownership.xml","form_type":"4"}},{"id":1033807,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70978,"kind":"person","name":"Bhatia Kishor G.","position":1,"cik":"0001812638","reported_name":"Bhatia Kishor G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:14.000Z","date":"2020-06-15","kind":"grant","planned":false,"acquired":true,"shares":52200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."}],"balance_after":52200,"derivative":{"exercise_price":5.04,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":52200},"source":{"system":"sec-edgar","filing":"0001493152-25-014615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1812638/000149315225014615/ownership.xml","form_type":"4"}},{"id":1033806,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70978,"kind":"person","name":"Bhatia Kishor G.","position":1,"cik":"0001812638","reported_name":"Bhatia Kishor G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:14.000Z","date":"2020-06-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":52200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":52200},"source":{"system":"sec-edgar","filing":"0001493152-25-014615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812638/000149315225014615/ownership.xml","form_type":"4"}},{"id":1452680,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70978,"kind":"person","name":"Bhatia Kishor G.","position":1,"cik":"0001812638","reported_name":"Bhatia Kishor G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-17T16:30:14.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing August 15, 2024."}],"balance_after":35000,"derivative":{"exercise_price":4.35,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001493152-24-028182","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812638/000149315224028182/ownership.xml","form_type":"4"}},{"id":2529120,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70978,"kind":"person","name":"Bhatia Kishor G.","position":1,"cik":"0001812638","reported_name":"Bhatia Kishor G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-02T16:06:27.000Z","date":"2021-10-29","kind":"grant","acquired":true,"shares":17400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing upon November 29, 2021."}],"balance_after":17400,"derivative":{"exercise_price":10.21,"expiration_date":"2031-10-29","underlying":"Common Stock","underlying_shares":17400},"source":{"system":"sec-edgar","filing":"0001213900-21-056109","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812638/000121390021056109/ownership.xml","form_type":"4"}},{"id":3110751,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70978,"kind":"person","name":"Bhatia Kishor G.","position":1,"cik":"0001812638","reported_name":"Bhatia Kishor G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2020-06-15T17:34:14.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":52200,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the employment agreement between the Issuer and the Reporting Person as Chief Scientific Officer, the Reporting Person was granted stock options to purchase 52,200 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (\"IPO\") under the terms and conditions of the Issuer's Amended and Restated 2018 Equity Incentive Plan. The exercise price equals the price per share sold in the Issuer's offering. One-third of the options will vest 180 days from the closing of the Issuer's IPO (the \"Grant Date\"), with the remaining two-thirds of the options vesting in equal monthly increments over the period commencing the 181st day after the Grant Date and ending 30 months thereafter (or 36 months after the Grant Date). Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the Grant Date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the employment agreement between the Issuer and the Reporting Person as Chief Scientific Officer, the Reporting Person was granted stock options to purchase 52,200 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (\"IPO\") under the terms and conditions of the Issuer's Amended and Restated 2018 Equity Incentive Plan. The exercise price equals the price per share sold in the Issuer's offering. One-third of the options will vest 180 days from the closing of the Issuer's IPO (the \"Grant Date\"), with the remaining two-thirds of the options vesting in equal monthly increments over the period commencing the 181st day after the Grant Date and ending 30 months thereafter (or 36 months after the Grant Date). Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the Grant Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the employment agreement between the Issuer and the Reporting Person as Chief Scientific Officer, the Reporting Person was granted stock options to purchase 52,200 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (\"IPO\") under the terms and conditions of the Issuer's Amended and Restated 2018 Equity Incentive Plan. The exercise price equals the price per share sold in the Issuer's offering. One-third of the options will vest 180 days from the closing of the Issuer's IPO (the \"Grant Date\"), with the remaining two-thirds of the options vesting in equal monthly increments over the period commencing the 181st day after the Grant Date and ending 30 months thereafter (or 36 months after the Grant Date). Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the Grant Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the employment agreement between the Issuer and the Reporting Person as Chief Scientific Officer, the Reporting Person was granted stock options to purchase 52,200 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (\"IPO\") under the terms and conditions of the Issuer's Amended and Restated 2018 Equity Incentive Plan. The exercise price equals the price per share sold in the Issuer's offering. One-third of the options will vest 180 days from the closing of the Issuer's IPO (the \"Grant Date\"), with the remaining two-thirds of the options vesting in equal monthly increments over the period commencing the 181st day after the Grant Date and ending 30 months thereafter (or 36 months after the Grant Date). Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the Grant Date."}],"balance_after":52200,"derivative":{"exercise_price":15,"underlying":"Common Stock","underlying_shares":52200},"source":{"system":"sec-edgar","filing":"0001213900-20-015050","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812638/000121390020015050/ownership.xml","form_type":"4"}}]}